An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...
